MK-3903 is a potent and selective AMPK activator (EC50 = 8 nM). MK-3903 binds moderately to the prostanoid DP2 (CRTH2) receptor (binding IC50=1.8 μM) but not in the presence of 10% human serum (binding IC50>86 μM).
In vivo, oral administration of MK-3903 (3, 10, and 30 mg/kg) to high-fructose fed db/+ mice results in significant inhibition of hepatic fatty acid synthesis (FAS) for all three doses.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 90 mg/mL|
 Ping Lan, et al. J Med Chem. Hit-to-Lead Optimization and Discovery of 5-((5-([1,1-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase
|Related AMPK Products|
Imm-h007 is an adenosine derivative that is an activator of the AMP-Activated Protein Kinase (AMPK).
BC1618, an orally active Fbxo48 inhibitor, stimulates Ampk signaling (preventing activated pAmpkα from being degraded by fBXO48-mediated proteasome). BC1618 promotes mitochondrial division, autophagy and insulin sensitivity in the liver.
O-304 is a pioneering, orally active pan-AMPK activator that increases AMPK activity by inhibiting dephosphorylation of pAMPK.
IM156, a metformin derivative, is an oxidative phosphorylation inhibitor that increases AMPK phosphorylation.
Pf-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 subtype with an EC50 value of 7 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.